The reality of drug pricing
By Andrew Willis | 01/03/19
High drug prices have been making headlines recently, with a recent U.S. Senate hearing into the matter earlier this week.
Should investors inject their portfolios with some pharma exposure to get behind this trend? Or are there dangerous side-effects to watch out for when getting behind companies selling thousand-dollar doses?
By Ambrose O’Callaghan The strategy of the United States Federal Reserve and its peers in the developed world had seemingly come into focus coming into 2024. In 2023, several statements from Fed chairman Jerome Powell led investors to believe that the first of several...
The Harvest Healthcare Leaders Income ETF (HHL) accesses value and growth opportunity in the healthcare space while providing monthly income.
Harvest ETFs CIO Paul MacDonald talks about the latest developments in healthcare, focusing on the impact of volatility and earnings and valuations from different sub-sectors. He also highlights where he sees potential opportunities in the industry.
Passive income investors get traditional asset allocation and covered call writing with the innovative Harvest Balanced Income & Growth ETF.
Harvest Portfolios Group Inc. (“Harvest”) announces the final March 2024 cash distribution for…
